Navigation Links
Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
Date:3/24/2011

erm=tarsa">www.clinicaltrials.gov/ct2/results?term=tarsa.

Tarsa is developing its oral calcitonin program under a licensing agreement with Unigene Laboratories that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.

About Osteoporosis

Osteoporosis is a common disease characterized by the loss of bone mass (thinning of bones) that leads to an increase in bone fragility and heightened risk of fractures. The National Osteoporosis Foundation reports that in the US, approximately 10 million individuals already have osteoporosis and an additional 34 million have low bone mass (also known as osteopenia), placing them at increased risk of developing osteoporosis.  The International Osteoporosis Foundation reports that osteoporosis affects an estimated 75 million people in the US, Europe and Japan.  Risk factors include family history, age, postmenopausal status, low dietary calcium intake, sedentary lifestyle and use of certain medications. As life spans increase globally, the number of individuals at risk of osteoporosis will continue to rise. At age 50, approximately one in two women and one in four men can expect to have an osteoporosis-related fracture during the remainder of their lives, with the risk increasing with age.  Fractures resulting from osteoporosis can be painful and debilitating, compromising the quality of patients' lives and in the case of hip fractures, increasing the risk of institutionalization, disability and early mortality.  For more information visit:  www.niams.nih.gov/HealthInfo/Bone or www.nof.org.

About Tarsa Therapeutics

Tarsa Therapeutics is developing an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.  Calcitonin ha
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... Even the hot Texas sun won’t keep ... . The school had previously invested in a ... from APCPLAY, but recently asked for an innovative solution to ... Godley Elementary School chose a Rectangular Shade from APCPLAY as ... on their playground. The shade measures 24’W x 34’H ...
(Date:7/11/2014)... Based in Pearland, Prime Urgent Care has ... County and surrounding counties. Recently, it improved access to ... from Northbound Highway 288 and Feeder Road. , Prime ... get low-cost urgent care of high quality. Although low-cost ... that can match the quality service level of the ...
(Date:7/10/2014)... July 10, 2014 Fatigue, lack ... an increasing number of accidents in the workplace, ... Reboot. The articles highlight safety issues that contribute ... million accidents occur on the job annually, according ... continue to explore "preventable workplace accidents." , Safety ...
(Date:7/10/2014)... July 11, 2014 According to ... Market by Platforms (Land, Airborne, Naval), Application (Software ... & by Geography (North America, Asia-Pacific, Europe, the ... (2014-2019)", published by MarketsandMarkets, the market is estimated ... expected to register a CAGR of 5.56% to ...
Breaking Medicine News(10 mins):Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Prime Urgent Care Announces New Access to the Clinic, Available from Northbound Highway 288 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4
... artemisinin yield from the herb Artemisia annua by specifying ... ,The two developments could bring down the ... Organization to treat malaria. Over 100 countries use it ... the drug chloroquine. ,A study, published in ...
... Legionnaires’ disease. // ,Jack Russell was admitted to ... of the bacteria Legionella pnuemophila, which causes the disease. ... It takes its name from the first known outbreak, which ... the Pennsylvania Department of the American Legion in 1976. ...
... of Pennsylvania School of Veterinary Medicine have derived uniparental ... eggs or two// sperm - and, for the first ... with healthy cells in adult mice. Their ... in an adult organ and could provide a less ...
... genes associated with the risk of developing Type II ... at risk a step closer. ,Researchers have ... that correspond to a risk of developing this life ... nearly 400,000 mutations in nearly 6,500 people. ...
... composer is just one of many blind people around the ... , Scientists working for the Doheny Eye ... a previous invention released in 2002; a prototype artificial retina. ... its successor, the Argus II Retinal Prosthesis System. ...
... come out with a device which is likely// to ... control issues. ,They have named this ... circuit in spinal cord which is responsible for the ... sustain continence. This device is extremely useful in patients ...
Cached Medicine News:Health News:Scientists Boost Production of Cheap Malaria Drugs 2Health News:Convict Felled by Legionnaires 2Health News:'single–parent' stem cells to replace adult mice organ 2Health News:'single–parent' stem cells to replace adult mice organ 3Health News:Genetic Test for Type II Diabetes Moves Closer 2Health News:Genetic Test for Type II Diabetes Moves Closer 3Health News:Bionic Eye may Restore Sight to the Blind 2Health News:Bladder Pacemaker For Incontinence 2Health News:Bladder Pacemaker For Incontinence 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: